New treatment options for various cancer therapies appear to be extremely expensive and prices may increase further. The affordability and availability of life-saving medicines is therefore a key issue in the national health policies of all countries. International and European law grant several price-reducing options, including compulsory licensing. Still, countries are reluctant to apply for compulsory licensing and/ or other regulatory options to curtail pharmaceutical prices. Why is that? Evaluating the options will support health policy decision-making on safeguarding access to affordable innovative medicines.

Additional Metadata
Keywords high-priced medicines – compulsory licensing – mandatory disclosure – competition law – joint procurement
Persistent URL hdl.handle.net/1765/129062
Journal European Journal of Health Law
Citation
den Exter, A.P. (2020). Fighting Excessive Pharmaceutical Prices: Evaluating the Options. European Journal of Health Law, (4). Retrieved from http://hdl.handle.net/1765/129062